This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SOUTH SAN FRANCISCO, Calif., Feb. 7, 2013 (GLOBE NEWSWIRE) -- diaDexus, Inc. (OTCQB:DDXS), a company developing and commercializing proprietary cardiovascular diagnostic products, today announced that Brian E. Ward, Ph.D., Chief Executive Officer, is scheduled to present at the Leerink Swann Global Healthcare Conference in New York. Dr. Ward will provide a corporate overview and update and will be available to conduct one-on-one meetings with investors.
Leerink Swann Global Healthcare Conference
February 14, 2013
1:30 pm ET
A live webcast of the presentation will be accessible on diaDexus' website at
www.diadexus.com . Please go to the website a few minutes early, as it may be necessary to download audio software to hear the presentation. A replay of the webcast will also be available after the conference concludes.
About diaDexus, Inc.
diaDexus, Inc., based in South San Francisco, California, develops and commercializes proprietary cardiovascular diagnostic products addressing unmet needs in cardiovascular disease. The company's PLAC® Test ELISA Kit is the only blood test cleared by the FDA to aid in predicting risk for both coronary heart disease and ischemic stroke associated with atherosclerosis, the #1 and #3 causes of death, respectively, in the United States. The company's PLAC® Test for Lp-PLA
2 Activity, a CE-marked test, is an indicator of atherosclerotic cardiovascular disease, the #1 cause of death in Europe. diaDexus is ISO 13485 certified and is manufacturing the PLAC Test for Lp-PLA
2 Activity on-site. For more information, please visit the company's website at
CONTACT: Company Contacts:
Brian E. Ward, Ph.D., CEO
Jean-Frederic Viret, Ph.D., CFO
The Ruth Group